PMID- 30373925
OWN - NLM
STAT- MEDLINE
DCOM- 20190819
LR  - 20190819
IS  - 1526-632X (Electronic)
IS  - 0028-3878 (Linking)
VI  - 91
IP  - 18
DP  - 2018 Oct 30
TI  - Reader response: Pregnancy decision-making in women with multiple sclerosis
      treated with natalizumab: I: Fetal risks.
PG  - 850
LID - 10.1212/WNL.0000000000006429 [doi]
FAU - Sotgiu, Stefano
AU  - Sotgiu S
AD  - (Sassari, Italy).
FAU - Eusebi, Anna
AU  - Eusebi A
AD  - (Sassari, Italy).
FAU - Begliuomini, Chiara
AU  - Begliuomini C
AD  - (Sassari, Italy).
FAU - Guerini, Franca R
AU  - Guerini FR
AD  - (Milan, Italy).
FAU - Carta, Alessandra
AU  - Carta A
AD  - (Sassari, Italy).
LA  - eng
PT  - Journal Article
PT  - Comment
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Natalizumab)
CON - Neurology. 2018 Mar 6;90(10):e823-e831. PMID: 29438046
CIN - Neurology. 2018 Oct 30;91(18):851. PMID: 30373926
MH  - Antibodies, Monoclonal, Humanized
MH  - Female
MH  - Humans
MH  - *Multiple Sclerosis
MH  - Natalizumab
MH  - Pregnancy
EDAT- 2018/10/31 06:00
MHDA- 2019/08/20 06:00
CRDT- 2018/10/31 06:00
PHST- 2018/10/31 06:00 [entrez]
PHST- 2018/10/31 06:00 [pubmed]
PHST- 2019/08/20 06:00 [medline]
AID - 91/18/850 [pii]
AID - 10.1212/WNL.0000000000006429 [doi]
PST - ppublish
SO  - Neurology. 2018 Oct 30;91(18):850. doi: 10.1212/WNL.0000000000006429.